Introduction
Methadone has been used to treat opioid dependence since the 1960s (1, 2) . Methadone is primarily metabolized by N-demethylation by cytochrome P450 3A4 (3) . N-Demethylation in combination with spontaneous cyclization results in formation of 2-ethylidene-l,5-dimethyl-3,3-diphenylpyrrolidine (EDDP). EDDP in turn is N-demethylated to 2-ethyl-5-methyl-3,3-diphenylpyrroline (EMDP). These two metabolites have no pharmacologic activity (4) . The pharmacologic half-life of methadone neccessitates daily administration to prevent opiate withdrawal (1, 2) . The structural analogue of methadone, l-(x-acetylmethadol (LAAM), has been known since the 1970s to also effectively prevent opioid withdrawal with administration every 2-3 days (5-7). The longer efficacy of LAAM appears to result from the N-demethylation of LAAM to active metabolites norLAAM and dinorLAAM (3, (8) (9) (10) . Based in part on a renewed interest in providing alternative medications to treat drug dependence, several recent clinical trials have resulted in U.S. Food and Drug Administration approval of LAAM as a substitute for methadone (11) .
In urine and other biologic tissues, methadol and its N-demethylation product, normethadol, have also been identified as metabolites of LAAM and methadone, respectively (4, 12) . Methadol would result from reduction of the ketone in methadone or from ester cleavage of the acetyl group from LAAM with subsequent N-demethylation leading to normethadol and potentially dinormethadol.
Methadone is often a component of urine drug-testing panels and emergency room and forensic toxicology exams. A number of commercial immunoassays exist for testing purposes. In methadone clinics, urine may be screened for methadone to assess treatment compliance (13) . In patients taking LAAM, they may be tested for methadone as an illicit drug. Because of the structural similarities between LAAM and its metabolites and methadone, we hypothesized that they could cross-react with methadone immunoassays, leading to false-positive results when screening for methadone. Fudala et al. (14) found that some samples that had screened positive for methadone by fluorescence polarization immunoassay (FPIA) had less than the cutoff concentration when analyzed by gas chromatography-mass spectrometry (GC-MS). These samples were also found to contain LAAM and its metabolites by GC-MS. The authors suggested that these false-positive results were due to LAAM cross-reactivity with the FPIA (14) .
To further test this hypothesis, drug-free urine was fortified with ascending concentrations of LAAM, norLAAM, dinor-LAAM, methadol, normethadol, dinormethadol, EDDP, or EMDP. The urines were analyzed by seven different commercial methadone immunoassays, and cross-reactivity relative to methadone was determined.
Materials and Methods

Materials
Methadone Blank urine was collected from human donors, pooled, and verified negative before use as blank, drug-free urine.
Standards
An inital stock solution for each analyte was prepared in distilled water at I mg/mL. These solutions were serially diluted with water to prepare working solutions at 100 pg/mL and 10 pg/mL for each analyte. The 1-mg/mL stock solutions were used to prepare 100-, 50-, 30-, 10-, 5-, and 3-pg/mL solutions in drug-free urine; the 100-pg/mL working solutions were used to prepare 1-, 0.5-and 0.3-pg/mL solutions in drug-free urine; and the 10-pg/mL working solutions were used to prepare 0.1-, 0.05-, and 0.03-pg/mL solutions in drug-free urine. Accuracy of the working solutions depended solely on the accuracies of the original weighings and subsequent dilutions.
Immunoassays
Immunoassays were performed in duplicate at each concentration of the analyte. The methadone solutions were included with each batch of assays as calibrators. Immunoassays were performed according to manufacturer's instructions using the following instrumentation: EIA-b (15) and EIA-d (16) were performed using a Syva ETS | plus system (Syva Co., Palo Alto, CA). The results were expressed as A absorbance/min. ELISA-d (17) and ELISA-s (18) were performed using an ELP-40 microplate strip washer and ELx 808 microplate reader (Bio-Tek Instruments, Inc., Winooski, VT). The absorbance results were expressed as B/B 0. FPIA (19) was performed on a TDx (Abbott Laboratories). The results were expressed as net polarization. KIMS (20) was performed on a Cobas Mira plus (Roche Diagnostic Systems). The results were expressed as %A absorbance. The RIA (21) cpm were obtained with a Cobra auto-gamma counter (Packard Instrument Co., Meriden, CT) and expressed as B/B o.
Cross-reactivity determination
For each assay, methadone results were plotted against the log concentration. The linear range for each assay was first determined from the range of consecutive methadone standards that gave the best correlation fit with signal The corresponding least-square equation was determined for the linear range. For nonmethadone analytes only signals within the linear range were used to determine cross-reactivity. Concentrations relative to methadone were determined using the calibration curves. These concentrations were divided by the fortified concentration of the analyte and multiplied by 100% to give percent cross-reactivity.
Results
The N-demethylation pathways of methadone and LAAM and the inter-relationship of the reduction of methadone and hydrolytic cleavage of LAAM are shown in Figure 1 . These compounds have been identified as the primary urinary metabolites of methadone and LAAM. Therefore, they are the most likely to contribute to an immuno-response in methadone immunoassays.
The linear range of methadone for each assay was determined using the in-house methadone calibrators fortified at ascending concentrations beginning at 0.03 pg/mL. The linear 
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Journal Figures 2--4 . The calculated cmss-reactivies of each analyte to each immunoassay is given in Table I . All of the immunoassays tested (except for EIA-b) showed good cross-reactivity with LAAM. The cross-reactivity (highest found given in parentheses) for LAAM using ELISA-d (321%), RIA (250%) (Table I) .
Discussion
In the current study we attempted to perform a complete survey of laboratory-dependent methadone-targeted immunoassay kits. All commercially available immunoassays for methadone that we could identify were studied with the exception of Microgenic's CEDIA | reagents. At the time of this study, the manufacturer of these reagents was not able to provide instructions for their use on the ETS system we had available for EIAs. For the same reason, we were not able to evaluate Microgenic's reagents that are targeted towards EDDP that are being developed. These have reported cross-reactivities towards LAAM that are extremely low (22) . This and other immunoassays directed towards EDDP may prove to be valuable when screens need to be specific for methadone use. Also not considered in this study, but of potential practical importance, are a number of on-site drug-testing devices that are available or being developed for detection of methadone.
To perform a uniform assessment of cross-reactivity of the immunoassay kits, all assays were compared using a single set of methadone calibrators prepared in-house. All calibration curves were generated using a linear fit of the log concentration versus immuno-response. The linear range of all assays encompassed the traditional methadone cutoff of 300 ng/mL, but varied between assays under the conditions of this study. EIA-b had the largest linear range, and RIA had the smallest. ELISA-d, ELISA-s, and RIA, however, all have potential to extend their linear ranges at the lower concentrations, had concentrations of LAAM, norLAAM, and dinorLAA in excess of 300 ng/rnL. This study demonstrated that LAAM can contribute to a positive methadone immunoassay result. It also supports our finding that FPIA had greater FPIA cross-reactivity for LAAM and/or its N-demethylation metabolites than EIA-b. In the Fudala et al. (14) study, the FPIA produced false-positive methadone test results in that the samples were immunoassay positive but did not contain more than 300 ng/mL methadone as determined by GC-MS. This is presumably due to the FPIA reactivity to LAAM and norLAAM. As most of the immunoassays considered in this study had even better crossreactivities for LAAM and nortAAM than the FPIA, it is reasonable to speculate that the other immunoassays would have even higher falsepostive rates if methadone were the primary test compound.
The study of Fudala et al. (14) only considered subjects who were being transferred to LAAM from methadone. These subjects, therefore, had not reached steady-state LAAM doses and urine concentrations of LAAM, norLAAM, and dinorLAAM were much lower than those anticipated in patients at steady-state. Reported urine concentrations of LAAM, norLAAM, and dinorLAAM in humans are limited to postmortem examinations when LAAM was being studied in the 1970s (23) and those in a single maintenance patient from a recent clinical trial (24) . In the postmortem cases, LAAM ranged from 50 to 1760 ng/mL, norLAAM ranged from 220 to 3040 ng/mL, and dinorLAAM ranged from 460 to 2000 ng/mL (23) . When the reported total excreted amounts (micrograms) from the single maintenance patient are converted to concentrations (nanograms per milliliter) the values ranged from 35 to 1140 ng/mL for LAAM, 355 to 4100 ng/mL for norLAAM, and 820 to 3650 ng/mL for dinorLAAM over the 72 h following the LAAM dose (24) . These concentrations are certainly sufficient to produce positive results in the immunoassays with high cross-reactivies for LAAM at time points when LAAM concentrations are high (LAAM was in excess of 400 ng/mL in all samples collected over the first 24 h). At later time points this may not be true, unless another metabolite, such as methadol, also has high cross-reactivity.
In general, the methadone immunoassay kits cross-reacted with methadol. Methadol and its N-demethyl-metabolite have been identified in the urine of humans taking LAAM or methadone (4, 12) . However, little is known about the quantitative contribution of the methadol metabolites to the total LAAM or methadone urine metabolites. Sullivan and Due (4) reported that approximately 3% of a methadone dose was excreted as normethadol. Methadone was 12% of the dose and EDDP 9% of the dose in the same study. Kaiko et al. (12) as these three tests had less than 50% binding for the lowest calibrator when compared with the blank urine ( Figures 3 and  4) . The linear range determined for these three assays was limited in part by our choice of low calibrators; however, with the exception of the RIA, our calibrators extended below the concentrations of those provided by the manufacturers. The linear range for all seven assays could also be increased with nonlinear curves such as four-point logistic curves. The cross-reactivity results demonstrate that methadone immunoassay kits have different antibody reactivity to LAAM, methadol, and their N-demethylation metabolites. The two EIAs displayed the greatest difference in reactivity. EIA-b was relatively specific for methadone; EIA-d had good cross-reactivities for the most analytes tested. It even had greater than 10% cross-reactivity for the cyclicized methadone metabolite, EDDP.
We generally found agreeable results with cross-reactivities listed in the package inserts with two exceptions. The RIA package insert lists the cross-reactivity with LAAM as 50 to 48% at LAAM concentrations of 200 to 500 ng/mL (21). We found cross-reactivities of 250 to 221% at these concentrations. The KIMS package insert listed the cross-reactivity with methadol as 120% at 250 ng/mL (20) . We found a cross-reactivity of 80% at 300 ng/mL.
Our results for EIA-b and FPIA agree with the findings reported by Fudala et al. (14) . They collected urine samples from subjects transferring from methadone to LAA treatment and tested the urines for methadone with EIA-b and FPIA. They also analyzed the urines for methadone, IAAM, norLAAM, and dinorLAAM by GC-MS. They found that 12 of the samples that tested positive by FPIA, two of which also tested positive by EIA-b, had less than the cutoff concentration, 300 ng/rnL, of methadone as determined by GC-MS. All 12 of these samples of methadone and LAAM, the contribution of methadol to the immunoassay results in urines of methadone or LAAM users remains to be determined.
The consequences of the findings of this study are several fold. Many methadone immunoassay kits may produce a positive result from the use of LAAM. This suggests that methadone immunoassay kits may be used to monitor LAAM compliance. However, this should be done cautiously because the immunoassay kits have varying cross-reactivity to LAAM and its metabolites. For forensic testing, a more comprehensive GC-MS confirmation may be required, if methadone is detected by the immunoassay to ensure that LAAM and metabolites are not also present in the sample. For emergency room testing, a urinalysis methadone-positive immunoassay result should be interpreted cautiously because LAAM or its metabolites have a longer duration of action than methadone.
